IFNA1 and neoplasm: Lower cAMP weakens Treg-mediated immunosuppression, releasing effector T cells (e.g., Th1 and cytotoxic T lymphocytes) from inhibition and indirectly amplifying IFN-driven anti-tumor and antiviral immunity [61, 62].